Beckman wins FDA nod for advanced test used in MI diagnosis

06/20/2013 | RTT News

The FDA has cleared Beckman Coulter, a unit of Danaher, to market its Access AccuTnI+3 troponin I test. The assay, which will run on the company's Access 2 immunoassay platform, has been shown in a clinical study to deliver precise as well as clinically sensitive and specific measurements to help doctors diagnose myocardial infarction.

View Full Article in:

RTT News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC